JohnELevineMDM.S.

Pediatric Hematology & Oncology • New York, NY

Professor of Internal Medicine and Pediatrics, Louis Aledort Clinical Research Professor in Hematology, Director of BMT Clinical Research

Join to view full profile

Dr. Levine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Levine's full profile

Already have an account?

Office
10 E 102nd St
New York, NY 10029
Phone+1 212-241-6756

Education & Training

Memorial Sloan Kettering Cancer Center1992 - 1995
Children's Hospital Los AngelesResidency, Pediatrics, 1989 - 1992
Eastern Virginia Medical SchoolClass of 1989

Certifications & Licensure

CA State Medical License 1990 - Present
FL State Medical License 2020 - Present
NY State Medical License 1992 - 2026
PA State Medical License 2016 - 2018
MI State Medical License 1995 - 2017
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants Start of enrollment: 2002 Sep 01
Completed
Phase 1, Phase 2
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Start of enrollment: 2003 Oct 01
Completed
Phase 2
Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) Start of enrollment: 2004 Aug 01
Completed
Phase 2
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Start of enrollment: 1997 Jan 01
Completed
Phase 2
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant Start of enrollment: 2003 Apr 01
Completed
Phase 2
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Start of enrollment: 2000 Mar 01
Terminated
Phase 2
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Start of enrollment: 2000 Mar 01
Completed
Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant Start of enrollment: 2009 Mar 01
Completed
Phase 2
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) Start of enrollment: 2008 Aug 01
Completed
Phase 2
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Start of enrollment: 2013 Mar 21
Completed
Phase 3
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Start of enrollment: 2016 Aug 01
Completed
Phase 2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2014 Aug 14
Completed
Phase 2
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) Start of enrollment: 2016 Nov 01
Completed
Phase 2
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Start of enrollment: 2018 Aug 17
Completed
Phase 2
Itacitinib for Low Risk GVHD Start of enrollment: 2019 Mar 25
Completed
Phase 2
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) Start of enrollment: 2019 Nov 21
Terminated
Phase 3
Pediatric GVHD Low Risk Steroid Taper Trial Start of enrollment: 2022 Oct 20
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) Start of enrollment: 2022 Jun 16
Terminated
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

9 citations
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year
Helen E. Heslop, Edward A. Stadtmauer, John E. Levine, Karen K. Ballen, Yi-Bin Chen
Transplantation and Cellular Therapy. 2021-11-01
144 citations
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shalini Shenoy, Mary Eapen, Julie A. Panepinto, Brent R. Logan, Juan Wu
Blood. 2016-11-24
485 citations
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.
Andrew C. Harris, Rachel Young, Steven M. Devine, William J. Hogan, Francis Ayuk
Biology of Blood and Marrow Transplantation. 2016-01-01

Journal Articles

Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic Leukemia
John E Levine, Muna Qayed, Stephan A Grupp, Eneida R Nemecek, Stella M Davies, Michael R Verneris, Michael Boyer, Jeffrey A Engelman, Nature

Abstracts/Posters

The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Everything You Need to Know About Graft-Versus-Host DiseaseJanuary 13th, 2023
Mount Sinai Researchers Find New, Safer Treatment for Serious Side Effect of Bone Marrow TransplantDecember 13th, 2022
An Experimental Cancer Treatment Leaves Two Patients 'Cured' After 10 YearsFebruary 18th, 2022
Join now to see all

Grant Support

Phase II Study Of A Novel GVHD Prevention Strategy: Etanercept And PhotopheresisNational Heart, Lung, And Blood Institute2011–2012
Cellular Immunotherapy For Hematologic MalignancyNational Cancer Institute2001–2006
Treatment Of Graft-Versus-Host Disease Using EnbrelFood And Drug Administration2005